Effect of Silymarin Administration on Cisplatin Nephrotoxicity: Report from A Pilot, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial

Phytotherapy Research

Volumn 29, Issue 7, 2015, Pages 1046-1053

  Shahbazi, Foroud ^a   Sadighi, Sanambar ^b   Dashti Khavidaki, Simin ^b   Shahi, Farhad ^b   Mirzania, Mehrzad ^b   Abdollahi, Alireza ^b   Ghahremani, Mohammad Hossein ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

cisplatin; milk thistle; nephrotoxicity; silymarin

Indexed keywords

ALKALINE PHOSPHATASE; CISPLATIN; CREATININE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; HEMOGLOBIN; IFOSFAMIDE; LIVER ENZYME; MAGNESIUM; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PACLITAXEL; PEMETREXED; PLACEBO; POTASSIUM; SILYMARIN; VINBLASTINE; ACUTE PHASE PROTEIN; LCN2 PROTEIN, HUMAN; LIPOCALIN; ONCOPROTEIN;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM CANCER; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INFUSION; FEMALE; HAIR LOSS; HUMAN; HYPERBILIRUBINEMIA; INCIDENCE; LEUKOPENIA; MAGNESIUM URINE LEVEL; MALE; MESOTHELIOMA; MIDDLE AGED; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; OVARY CANCER; PATIENT COMPLIANCE; PILOT STUDY; POTASSIUM URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; RASH; RENAL SYSTEM PARAMETERS; SIDE EFFECT; THROMBOCYTOPENIA; URINE NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN TO URINE CREATININE RATIO; VOMITING; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; KIDNEY; KIDNEY FUNCTION TEST; URINE;

SILYBUM MARIANUM;

ACUTE KIDNEY INJURY; ACUTE-PHASE PROTEINS; ADULT; CISPLATIN; CREATININE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; LIPOCALINS; MAGNESIUM; MALE; MIDDLE AGED; PILOT PROJECTS; POTASSIUM; PROTO-ONCOGENE PROTEINS; SILYMARIN;

EID: 84936852686     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5345     Document Type: Article

References (41)

1. Abu-Surrah AS, Kettunen M,. 2006. Platinum group antitumor chemistry: design and development of new anticancer drugs complementary to cisplatin. Curr Med Chem 13: 1337-1357.
2. Agarwal R, Agarwal C, Ichikawa H, Singh RP, Aggarwal BB,. 2006. Anticancer potential of silymarin: from bench to bed side. Anticancer Res 26: 4457-4498.
3. Arany I, Safirstein RL,. 2003. Cisplatin nephrotoxicity. Semin Nephrol 23: 460-464.
4. Blachley JD, Hill JB,. 1981. Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med 95: 628-632.
5. Bokemeyer C, Fels LM, Dunn T, et al., 1996. Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity. Br J Cancer 74: 2036-2041.
6. Brantley SJ, Oberlies NH, Kroll DJ, Paine MF,. 2010. Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations. J Pharmacol Exp Ther 332: 1081-1087.
7. Calani L, Brighenti F, Bruni R, Del Rio D,. 2012. Absorption and metabolism of milk thistle flavanolignans in humans. Phytomedicine 20: 40-46.
8. Coca SG, Singanamala S, Parikh CR,. 2012. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int 81: 442-448.
9. Common Terminology Criteria for Adverse Events V4.0 (CTCAE). 2013. Available from http://ctep.cancer.gov/protocoldevelopment/electronic-applications/ctc.htm, (Accessed on June 4, 2014). Last updated 2013.
10. Cvitkovic E,. 1998. Cumulative toxicities from cisplatin therapy and current cytoprotective measures. Cancer Treat Rev 24: 265-281.
11. De Geus HR, Betjes MG, Bakker J,. 2012. Biomarkers for the prediction of acute kidney injury: a narrative review on current status and future challenges. Clin Kidney J 5: 102-108.
12. Devarajan P,. 2014. NGAL for the detection of acute kidney injury in the emergency room. Biomark Med 8: 217-219.
13. Dos Santos NA, Carvalho Rodrigues MA, Martins NM, dos Santos AC,. 2012. Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Arch Toxicol 86: 1233-1250.
14. Gaedeke J, Fels LM, Bokemeyer C, Mengs U, Stolte H, Lentzen H,. 1996. Cisplatin nephrotoxicity and protection by silibinin. Nephrol Dial Transplant 11: 55-62.
15. Gaspari F, Cravedi P, Mandalà M, et al., 2010. Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case-control study. Nephron Clin Pract 115: c154-c160.
16. Hamdi T, Latta S, Jallad B, Kheir F, Alhosaini MN, Patel A,. 2010. Cisplatin-induced renal salt wasting syndrome. South Med J 103: 793-799.
17. Hartmann JT, Fels LM, Franzke A, et al., 2000. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide. Anticancer Res 20: 3767-3773.
18. Hawke RL, Schrieber SJ, Soule TA, et al., 2010. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol 50: 434-449.
19. Ho PM, Bryson CL, Rumsfeld JS,. 2009. Medication adherence. Its importance in cardiovascular outcome. Circulation 119: 3028-3035.
20. Javed S, Kohli K, Ali M,. 2011. Reassessing bioavailability of silymarin. Altern Med Rev 16: 239-249.
21. Karimi G, Ramezani M, Tahoonian Z,. 2005. Cisplatin nephrotoxicity and protection by milk thistle extract in rats. Evid Based Complement Alternat Med 2: 383-386.
22. Kos FT, Sendur MA, Aksoy S, et al., 2013a. Evaluation of renal function using the level of neutrophil gelatinase-associated lipocalin is not predictive of nephrotoxicity associated with cisplatin-based chemotherapy. Asian Pac J Cancer Prev 14: 1111-1114.
23. Kos FT, Sendur MA, Aksoy S, et al., 2013b. Evaluation of the renal function using cystatin C level in the patients receiving cisplatin-based chemotherapy. Ren Fail 3: 705-710.
24. Ladas EJ, Kroll DJ, Oberlies NH, et al., 2010. A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL). Cancer 116: 506-513.
25. Lajer H, Daugaard G,. 1999. Cisplatin and hypomagnesemia. Cancer Treat Rev 25: 47-58.
26. Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M,. 2008. Prevention of cisplatin nephrotoxicity: state of the art and recommendation from the European Society of Clinical Pharmacy special interest group on cancer care. Cancer Chemother Pharmacol 61: 903-909.
27. Lin HY, Lee SC, Lin SF, et al., 2013. Urinary neutrophil gelatinase-associated lipocalin levels predict cisplatin-induced acute kidney injury better than albuminuria or urinary cystatin C levels. Kaohsiung J Med Sci 29: 304-311.
28. Litterst CL, Torres IJ, Guarino AM,. 1977. Plasma levels and organ distribution of platinum in the rat, dog, and dog fish following intravenous administration of cis-DDP [II]. J Clin Hematol Oncol 7: 169-178.
29. Madias NE, Harrington JT,. 1978. Platinum nephrotoxicity. Am J Med 65: 307-314.
30. Mehta RL, Kellum JA, Shah SV, et al., 2007. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11: R31.
31. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB,. 2010. Mechanisms of cisplatin nephrotoxicity. Toxins (Basel) 2: 2490-2518.
32. Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P,. 2004. Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 24: 307-315.
33. Moon HH, Seo KW, Yoon KY, Shin YM, Choi KH, Lee SH,. 2011. Prediction of nephrotoxicity induced by cisplatin combination chemotherapy in gastric cancer patients. World J Gastroenterol 17: 3510-3517.
34. Nan-Ya KI, Kajihara M, Kojima N, Degawa M,. 2014. Usefulness of urinary kidney injury molecule-1 (Kim-1) as a biomarker for cisplatin-induced sub-chronic kidney injury. J Appl Toxicol. doi: 10.1002/jat.2999. [Epub ahead of print].
35. Nielsen SE, Schjoedt KJ, Astrup AS, et al., 2010. Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril. Diabet Med 27: 1144-1150.
36. Rose BD,. 2014. Evaluation of the patient with hypokalemia. Available from: www.UpToDate.com [Accessed on June 4, 2014].
37. Saller R, Meier R, Brignoli R,. 2001. The use of silymarin in the treatment of liver diseases. Drugs 61: 2035-2063.
38. Sanchez-Gonzalez PD, Lopez-Hernandez FJ, Perez-Barriocanal F, Morales AI, Lopez-Novoa JM,. 2011. Quercetin reduces cisplatin nephrotoxicity in rats without compromising its anti-tumour activity. Nephrol Dial Transplant 26: 3484-3495.
39. Sprowl JA, van Doorn L, Hu S, et al., 2013. Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance. Clin Pharmacol Ther 94: 585-592.
40. Yousef MM, Helal OK, Adly N,. 2011. Effect of silymarin on cisplatin-induced renal tubular injuries in adult male rabbits: a histological, immunohistochemical, and electron microscopic study. Egypt J Histol 34: 800-807.
41. Yu ASL,. 2014. Evaluation and treatment of hypomagnesemia. Available from: www.UpToDate.com [Accessed on June 4, 2014].